Why EGFR Drugs Fail in Glioblastoma: A STAT3 Escape Route Takes Center Stage
A new review argues that glioblastoma evades EGFR-targeted therapies through compensatory STAT3 activation, positioning the EGFR–STAT3 axis as an adaptive ...
A new review argues that glioblastoma evades EGFR-targeted therapies through compensatory STAT3 activation, positioning the EGFR–STAT3 axis as an adaptive ...
A new review argues that dry eye disease is sustained by a self-amplifying inflammatory circuit linking the corneal epithelium, immune ...
A new preclinical study shows that the β-catenin/CBP inhibitor ICG-001 selectively kills endometrial cancer cells carrying both PIK3CA and CTNNB1 ...
A 563-patient genomic study from Peking University reveals how KMT2C/D loss-of-function alterations define a hypermutated, MSI-high subgroup of gastric cancer ...
A Phase 1 trial found that combining the ATR inhibitor ceralasertib with the PARP inhibitor olaparib was generally well tolerated ...
A new Nature Reviews Clinical Oncology review charts how HER2-targeted therapies, led by trastuzumab deruxtecan, are driving a shift from ...
Sylvester Comprehensive Cancer Center researchers report an FDA approval for a pancreatic cancer pill that nearly doubled survival, alongside new ...
A new review in Aging Cell positions endothelial TLR4 as a context-dependent molecular rheostat controlling vascular senescence, arguing that precision ...
UCLA oncologist Dr. Dennis Slamon has received the 2026 Albany Prize for discoveries that identified HER2-positive breast cancer and produced ...
A Dutch registry study finds the number of patients living long-term with de novo metastatic incurable cancer more than quadrupled ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine